Secondary preventive drug use for acute coronary syndromes in France

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.380, 2002-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France

By Bezin J. Pariente A. Lassalle R. Dureau-Pournin C. Abouelfath A. Robinson P. Moore N. Droz-Perroteau C. Fourrier-Reglat A.

European Journal of Clinical Pharmacology, Vol. 70, Iss. 4, 2014-04 ,pp. : 429-436

Springer Publishing Company

Access to resources Recommend Favorite

Tirofiban: A Review of its Use in Acute Coronary Syndromes

By McClellan K.J. Goa K.L.

Drugs, Vol. 56, Iss. 6, 1998-12 ,pp. : 1067-1080

Adis International

Access to resources Recommend Favorite

Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes

By Kassab Yaman

International Journal of Clinical Pharmacy, Vol. 35, Iss. 2, 2013-04 ,pp. : 275-280

Springer Publishing Company

Access to resources Recommend Favorite

Fondaparinux in acute coronary syndromes

By Chaturvedi Vivek Karthikeyan Ganesan

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 12, 2009-12 ,pp. : 1615-1623

Informa Healthcare

Access to resources Recommend Favorite

Acute Coronary Syndromes in the Elderly

By Kyriakides Zenon S. Kourouklis Spyros Kontaras Konstantinos

Drugs & Aging, Vol. 24, Iss. 11, 2007-01 ,pp. : 901-912

Adis International

Access to resources Recommend Favorite